Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database

Prostate

Volumn 73, Issue 4, 2013, Pages 409-417

  Abern, Michael R ^a   Aronson, William J ^b,c   Terris, Martha K ^d,e   Kane, Christopher J ^f   Presti, Joseph C ^g,h   Amling, Christopher L ⁱ   Freedland, Stephen J ^a,j  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VA PALO ALTO HEALTH CARE SYSTEM   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j DURHAM VA MEDICAL CENTER   (United States)

more..

Author keywords

active surveillance; prostatectomy; prostatic neoplasms; retropubic; treatment outcome

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CORRELATION ANALYSIS; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSITIVE SURGICAL MARGIN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; THERAPY DELAY; TREATMENT OUTCOME;

EID: 84872963407     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22582     Document Type: Article

References (31)

1. van Leeuwen PJ, van Vugt HA, Bangma CH,. The implementation of screening for prostate cancer. Prostate Cancer Prostatic Dis 2010; 13 (3): 218-227.
2. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB,. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29 (16): 2185-2190.
3. Krakowsky Y, Loblaw A, Klotz L,. Prostate cancer death of men treated with initial active surveillance: Clinical and biochemical characteristics. J Urol 2010; 184 (1): 131-135.
4. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B,. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181 (4): 1635-1641; discussion 1641.
5. Hernandez DJ, Nielsen ME, Han M, Partin AW,. Contemporary evaluation of the D'Amico risk classification of prostate cancer. Urology 2007; 70 (5): 931-935. (Pubitemid 350192614)
6. Iremashvili V, Manoharan M, Pelaez L, Rosenberg DL, Soloway MS,. Clinically significant Gleason sum upgrade: External validation and head-to-head comparison of the existing nomograms. Cancer 2011. Epub 2011/07/07.
7. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr., Upgrading and downgrading of prostate needle biopsy specimens: Risk factors and clinical implications. Urology 2007; 69 (3): 495-499. (Pubitemid 46428381)
8. Colleselli D, Pelzer AE, Steiner E, Ongarello S, Schaefer G, Bartsch G, Schwentner C,. Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis 2010; 13 (2): 182-185.
9. Corcoran NM, Hovens CM, Hong MK, Pedersen J, Casey RG, Connolly S, Peters J, Harewood L, Gleave ME, Goldenberg SL, Costello AJ,. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 2011. Epub 2011/09/08.
10. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD,. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180 (5): 1964-1968.
11. King AC, Livermore A, Laurila TAJ, Huang W, Jarrard DF,. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol 2011. Epub 2011 Aug 2.
12. Shibata A, Mohanasundaram UM, Terris MK,. Interval from prostate biopsy to radical prostatectomy: Effect on PSA, Gleason sum, and risk of recurrence. Urology 2005; 66 (4): 808-813. (Pubitemid 41440829)
13. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR,. Surgical management after active surveillance for low-risk prostate cancer: Pathological outcomes compared with men undergoing immediate treatment. BJU Int 2011; 107 (8): 1232-1237.
14. van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schroder FH, Hugosson J,. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010; 116 (5): 1281-1290.
15. Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J,. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?-A case control study. Scand J Urol Nephrol 2003; 37: 213-217. (Pubitemid 36791819)
16. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW,. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 2004; 172 (5 Pt 1): 1835-1839. (Pubitemid 39363068)
17. Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A, Ho M, Evans A, Sweet J, Trachtenberg J,. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 2003; 10 (3): 1891-1898.
18. Thompson IM, Klotz L,. Active surveillance for prostate cancer. JAMA 2010; 304 (21): 2411-2412.
19. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC,. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010; 8 (2): 162-200.
20. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28 (1): 126-131.
21. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR,. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29 (2): 228-234.
22. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280 (11): 969-974. (Pubitemid 28445094)
23. O'Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, Catalona WJ,. Delay of surgery in men with low risk prostate cancer. J Urol 2011; 185 (6): 2143-2147.
24. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK,. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 2006; 175 (4): 1298-1302; discussion 302-3. Epub 2006/03/07.
25. Wilt T,. Prostate cancer intervention versus observation trial (PIVOT)-Main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Washington DC: American Urologic Association Annual Meeting; 2011.
26. Daskivich TJ, van de Poll-Franse LV, Kwan L, Sadetsky N, Stein DM, Litwin MS,. From bad to worse: Comorbidity severity and quality of life after treatment for early-stage prostate cancer. Prostate Cancer Prostatic Dis 2010; 13 (4): 320-327.
27. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294 (4): 433-439. (Pubitemid 41124175)
28. Choueiri TK, Chen M-H, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW,. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010; 116 (8): 1887-1892.
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25 (13): 1765-1771. (Pubitemid 46797959)
30. Vickers AJ, Bianco FJ, Boorjian S, Scardino PT, Eastham JA,. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006; 106 (3): 576-580. (Pubitemid 43157620)
31. Banez LL, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ,. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?-Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 2009; 18 (4): 1208-1212.